Lista de obras -

18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis

artículo científico publicado en 2017

A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases

artículo científico publicado en 2019

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

artículo científico publicado en 2010

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers

artículo científico publicado en 2010

Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer ⬇️

artículo científico publicado el 8 de mayo de 2013

Distinct tumor protein p53 mutants in breast cancer subgroups

artículo científico publicado en 2012

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

artículo científico publicado en 2007

High expression of apoptosis protein (Api-5) in chemoresistant triple-negative breast cancers: an innovative target

scientific article published on 12 November 2019

Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer

artículo científico publicado en 2002

Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status

artículo científico publicado en 2017

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.

artículo científico publicado en 2013

Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.

artículo científico publicado en 2014

Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC

scientific article published on 17 September 2020

Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer

artículo científico publicado en 2012

TP53 status and response to chemotherapy in breast cancer

artículo científico publicado en 2008

Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer

artículo científico publicado en 2017

The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study

artículo científico publicado en 2011

Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse

artículo científico publicado en 2012

p53 in breast cancer subtypes and new insights into response to chemotherapy

artículo científico

¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer

artículo científico publicado en 2014

Lista de obras de

18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis

A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers

Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer ⬇️

Distinct tumor protein p53 mutants in breast cancer subgroups

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

High expression of apoptosis protein (Api-5) in chemoresistant triple-negative breast cancers: an innovative target

Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer

Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.

Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.

Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC

Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer

TP53 status and response to chemotherapy in breast cancer

Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer

The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study

Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse

p53 in breast cancer subtypes and new insights into response to chemotherapy

¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer